Skyline Ventures

Skyline Ventures invests exclusively in human healthcare, targeting early-stage therapeutics, medical devices, and digital health companies. The firm typically leads or co-leads first institutional rounds and concentrates its portfolio on fewer than 20 active positions per fund. Its geographic focus has historically centered on the West Coast biotech corridor.

John Freund, a Harvard-trained physician and former Acuson executive, co-founded the firm and serves as Managing Director. The partnership is built around physician-investors with clinical and product-development operating experience, meaning investment decisions are made by partners with direct practice or device-industry backgrounds rather than solely by career finance professionals.

Skyline operates as a direct investor, taking equity positions in portfolio companies rather than making fund-of-fund commitments. The firm leads or co-leads early-stage rounds and may participate in later-stage PIPEs for existing portfolio companies, but does not function as a limited partner in other venture funds.

Acclarent, an ENT surgical device company backed by Skyline, was acquired by Johnson & Johnson's Ethicon unit. The deal validated Skyline's approach of backing specialist surgical-device platforms in concentrated markets. Other realized positions include Xoft, which developed intraoperative radiation therapy technology.

Skyline has maintained a deliberately lean structure and concentrated portfolio model, operating with a small team of physician-investors rather than building a large multi-sector platform. Unlike generalist Bay Area firms that added healthcare practices over time, Skyline has been exclusively healthcare-focused since its 1997 founding and has not expanded into growth equity, public markets, or non-healthcare sectors.